<DOC>
	<DOCNO>NCT00907322</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics Dimebon follow single ascend dos . A formal single ascend dose study nature perform date Dimebon development program .</brief_summary>
	<brief_title>A Phase 1 Trial To Assess The Safety And Pharmacokinetics Of Single , Ascending , Oral Doses Of Dimebon In Healthy Adults</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive . Subjects display CYP2D6 extensive , intermediate , ultrarapid , poor metabolizer status . A known history hypersensitivity previous intolerance Dimebon antihistamine . Subjects previous history seizure , convulsion , epilepsy , significant head injury . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>oral , single ascending dos ; CYP2D6 metabolizer status ; healthy subject ; safety , tolerability , pharmacokinetics</keyword>
</DOC>